



ADCs



Phase I study of raludotatug deruxtecan (R-DXd; DS-6000) monotherapy

- CDH6 is expressed in 65-85% of ovarian cancers
- Patients for study were not selected on basis of CDH6 expression
- Advanced/metastatic ovarian cancer not amenable to SOC therapy
- All platinum and taxane-pretreated
- Analysis of patients receiving 4.8-8.0 mg/kg doses



- **Confirmed ORR: 46%** in the 4.8–8.0 mg/kg OVC cohort (23/50; 95% CI: 32–61); one CR and 22 PRs
 - 4 unconfirmed responses were ongoing at data cutoff
- **Disease control rate^a: 98%**